Table 3.
Frequency of alloantibodies compared to age and sex parameters
| Age |
Number
of patients |
Number of
patients with alloantibodies |
Anti-D | Anti-C | Anti-E | Anti-K | Anti-JK a | Anti-Fy a |
|---|---|---|---|---|---|---|---|---|
| 92 | 1 (2.9%) |
0 | 0 | 0 | 1 (2.9%) |
0 | 0 | |
| 11-19 | 130 | 14 (41.2%) |
3 (8.8%) |
2 (5.8%) |
3 (8.8%) |
6 (17.6%) |
0 | 0 |
| 20-28 | 134 | 11 (32.4%) |
4 (11.7%) |
2 (5.8%) |
0 | 3 (8.8%) |
0 | 1 (2.9%) |
| 29-38 | 71 | 6 (17.6%) |
1 (2.9%) |
0 | 2 (5.8%) |
3 (8.8%) |
1 (2.9%) |
0 |
| 39-47 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 48-56 | 6 | 1 (2.9%) |
0 | 0 | 0 | 0 | 0 | 0 |
| 57+ | 2 | 1 (2.9%) |
0 | 1 (2.9%) |
0 | 0 | 0 | 0 |
| Total | 446 | 34 | 8 (23.5%) |
5 (14.7%) |
5 (14.7%) |
13 (38.2%) |
1 (2.9%) |
1 (2.9%) |
| Gender | ||||||||
| Male | 249 | 14 (3.1%) |
2 (14.2%) |
2 (14.2%) |
3 (21.4%) |
7 (50%) |
0 | 0 |
| Female | 197 | 20 (4.4%) |
6 (30%) |
3 (15%) |
2 (10%) |
6 (30%) |
1 (5%) |
1 (5%) |